



May 19, 2024

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
MUMBAI - 400 001

**National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
MUMBAI - 400 051

**Dear Sir/Madam,**

**Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Subject: U.S. FDA Inspection of the Company's Somerset manufacturing facility**

We would like to inform you that the U.S. FDA concluded a Pre Approval Inspection at Lupin's Somerset, New Jersey manufacturing facility. The inspection was conducted from May 7, 2024 to May 17, 2024, and closed with an issuance of a Form-483 with six observations.

We are addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**